March 5, 2026 — Leads & Copy — Silence Therapeutics plc (Nasdaq: SLN) reported its financial results for the fourth quarter and full year, which ended Dec. 31, 2025, and provided an update on recent business achievements.
According to Iain Ross, Chairman and Interim Principal Executive Officer at Silence, the company focused on clinical execution throughout the past year. The Phase 2 SANRECO trial of divesiran in PV is enrolling patients faster than expected and remains on track for topline results in the third quarter of 2026.
Divesiran, a first-in-class siRNA product candidate in PV with broad potential in blood disorders, is the company’s highest priority. Ross said Silence is well positioned with excellent optionality and multiple near-term value drivers.
The company also reported the following business highlights:
Divesiran: First-in-class siRNA for PV
The topline results in the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for PV, are anticipated in 3Q’26, accelerated from the original estimate of 2H’26. The adjustment is due to faster-than-expected enrollment.
Zerlasiran: Phase 3 ready program for cardiovascular disease due to high Lp(a)
Core Phase 3 readiness activities are complete, positioning the program for a potential third-party partner to initiate Phase 3 development.
SLN312: Phase 1 siRNA with a competitive profile for dyslipidemia
AstraZeneca shared results from an interim analysis of a Phase 1 randomized, single-blind, placebo-controlled trial of SLN312 in 98 patients with dyslipidemia. SLN312 is an siRNA silencing ANGPTL3 discovered using Silence’s mRNAi GOLD™ platform and developed by AstraZeneca. Highlights include:
SLN312 demonstrated durable dose-dependent reductions in ANGPTL3, triglycerides and atherogenic lipoproteins after single and multiple doses.
A strong durability profile was observed, supporting the potential for infrequent dosing.
SLN312 was well tolerated, with no safety concerns identified.
Phase 1 data presentations are planned for medical and research congresses in 2026.
AstraZeneca notified Silence on March 4, 2026, that it will not pursue further development of SLN312 beyond Phase 1. Silence will regain exclusive rights globally to this clinical asset following Phase 1 and is evaluating plans for further development. AstraZeneca and Silence maintain a broader collaboration leveraging Silence’s mRNAi GOLD™ platform for cardiovascular, cardiometabolic, renal and respiratory diseases.
The company also reported the following discovery pipeline developments:
Promising preclinical data was generated for two new mRNAi GOLD™ platform programs.
SLN365, a potential first-in-class siRNA silencing GPR146, is a novel mechanism-of-action for cholesterol management independent of LDL-C receptor function.
SLN098, an siRNA silencing INHBE, is a novel target for obesity supported by human genetics and strong pre-clinical data.
The company advanced extra-hepatic cell targeting leveraging its proprietary siRNA platform, generating promising preliminary results in several cell types.
The anticipated 2026 milestones include:
Topline results for Phase 2 SANRECO trial of divesiran in PV in third quarter of 2026.
Additional preclinical data for SLN365 (GPR146) in second quarter of 2026.
Additional preclinical data for SLN098 (INHBE) in second quarter of 2026.
Phase 1 data presentations for SLN312 at medical and research congresses in 2026.
Corporate updates include:
Iain Ross, Chairman of the Board of Directors, was announced as Interim Principal Executive Officer on Dec. 15, 2025, following the departure of the Company’s former CEO; a search is underway for a new CEO.
In December 2025, James Ede Golightly, a former Silence Non-Executive Director, was reappointed to the Board. Additionally, Rhonda Hellums, CFO of Silence, was appointed to the Board as an Executive Director.
Full year 2025 financial results include:
Cash Position: Cash, cash equivalents, and short-term investments were $85.1 million as of December 31, 2025. This includes cash and cash equivalents of $11.3 million and short-term investments of $73.8 million.
Collaboration Revenue: Collaboration revenue was $0.6 million for the year ended December 31, 2025, compared to $43.3 million for the year ended December 31, 2024. The decrease for 2025 was primarily due to revenue associated with the Hansoh collaboration that concluded in 2024 and a $17.4 million decrease in revenue related to the AstraZeneca collaboration.
R&D Expenses: Research and development (R&D) expenses were $67.8 million for the year ended December 31, 2025, compared to $67.9 million for the year ended December 31, 2024.
G&A Expenses: General and administrative (G&A) expenses were $22.3 million for the year ended December 31, 2025, compared to $26.9 million for the year ended December 31, 2024. The decrease for 2025 was primarily a result of a decrease in SEC reporting requirements and other cost-savings initiatives.
Net Loss: Net loss was $88.6 million, or $0.63 basic and diluted net loss per share for the year ended December 31, 2025, compared to a net loss of $45.3 million, or $0.33 basic and diluted net loss per share for the year ended December 31, 2024.
Total outstanding shares were 141,701,848 ordinary shares (including shares in the form of American Depositary Shares) as of December 31, 2025.
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate.
Source: Silence Therapeutics
